Page last updated: 2024-12-08

norcisapride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

norcisapride: metabolite of cisapride [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3019427
CHEMBL ID1748
CHEBI ID186415
SCHEMBL ID593405
MeSH IDM0195349

Synonyms (21)

Synonym
norcisapride
CHEMBL1748 ,
bdbm50301927
CHEBI:186415
4-amino-5-chloro-2-methoxy-n-(3-methoxypiperidin-4-yl)benzamide
84946-16-7
A841018
4-amino-5-chloro-2-methoxy-n-(3-methoxy-4-piperidyl)benzamide
einecs 284-619-3
FT-0673057
(4-amino-5-chloro-2-methoxy)-n-[3-methoxy(4-piperidyl)]benzamide
SCHEMBL593405
4-amino-5-chloro-2-methoxy-n-(3-methoxy-4-piperidinyl)benzamide
4-amino-5-chloro-2-methoxy-n-(3-methoxy-piperidin-4-yl)-benzamide
OMLDMGPCWMBPAN-UHFFFAOYSA-N
sr-01000944814
SR-01000944814-1
AKOS030254741
FT-0741192
(4-amino-5-chloro-2-methoxy)-n-(3-methoxy(4-piperidyl))benzamide
DTXSID00870220

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacodynamic effect of cisapride was measured by means of radionuclide gastric emptying."( Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis.
Bares, R; Dakshinamurty, KV; Gladziwa, U; Ittel, TH; Klotz, U; Seiler, KU; Sieberth, HG, 1991
)
0.28

Dosage Studied

ExcerptRelevanceReference
" Cisapride dosage adjustment or substitution after hemodialysis is not necessary."( Pharmacokinetics and pharmacodynamics of cisapride in patients undergoing hemodialysis.
Bares, R; Dakshinamurty, KV; Gladziwa, U; Ittel, TH; Klotz, U; Seiler, KU; Sieberth, HG, 1991
)
0.28
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzamides
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3AHomo sapiens (human)IC50 (µMol)1.60000.00011.07899.0000AID447476
5-hydroxytryptamine receptor 4Homo sapiens (human)IC50 (µMol)0.01900.00020.10210.4830AID447477
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3AHomo sapiens (human)EC50 (µMol)2.30000.00100.65503.8000AID447480
5-hydroxytryptamine receptor 4Homo sapiens (human)EC50 (µMol)0.29000.00060.08791.1220AID447479
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
maintenance of gastrointestinal epithelium5-hydroxytryptamine receptor 4Homo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 4Homo sapiens (human)
mucus secretion5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
large intestinal transit5-hydroxytryptamine receptor 4Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 4Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 4Homo sapiens (human)
serotonin receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 4Homo sapiens (human)
endosome5-hydroxytryptamine receptor 4Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
membrane5-hydroxytryptamine receptor 4Homo sapiens (human)
synapse5-hydroxytryptamine receptor 4Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID447479Agonist activity at human recombinant 5-HT4 receptor2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I).
AID447480Antagonist activity at human recombinant 5-HT3 receptor expressed in HEK293 cells2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I).
AID447476Displacement of [3H]granisetron from human recombinant 5-HT3 receptor expressed in HEK293 cells2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I).
AID447477Displacement of [3H]GR-113808 from human recombinant 5-HT4 receptor2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (37.50)18.2507
2000's5 (62.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (37.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (62.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]